{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T16:56:29Z","timestamp":1773248189044,"version":"3.50.1"},"reference-count":24,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Oklahoma City VA Medical Center (Oklahoma City, OK)"},{"name":"Veterans Health Administration (VHA)"},{"name":"Corporate Data Warehouse (CDW)"},{"name":"Sundaragandhi Radhakrishnan (VINCI Data Manager of the VHA CDW)"}],"content-domain":{"domain":["clinicalkey.jp","ijaaonline.com","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1016\/j.ijantimicag.2016.11.018","type":"journal-article","created":{"date-parts":[[2017,1,17]],"date-time":"2017-01-17T17:52:18Z","timestamp":1484675538000},"page":"333-338","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["A propensity score-matched analysis of the impact of minimum inhibitory concentration on mortality in patients with Pseudomonas aeruginosa bacteraemia treated with piperacillin\/tazobactam"],"prefix":"10.1016","volume":"49","author":[{"given":"Chris A.","family":"Gentry","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"II","given":"Riley J.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2016.11.018_bib0010","first-page":"1","article-title":"Deaths: leading causes for 2009","volume":"61","author":"Heron","year":"2012","journal-title":"Natl Vital Stat Rep"},{"key":"10.1016\/j.ijantimicag.2016.11.018_bib0015","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1086\/421946","article-title":"Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study","volume":"39","author":"Wisplinghoff","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2016.11.018_bib0020","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1001\/archinte.1996.00440170139015","article-title":"Epidemiology and outcome of Pseudomonas aeruginosa bacteremia, with special emphasis on the influence of antibiotic treatment. Analysis of 189 episodes","volume":"156","author":"Vidal","year":"1996","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ijantimicag.2016.11.018_bib0025","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1093\/cid\/cit017","article-title":"Background and rationale for revised Clinical and Laboratory Standards Institute interpretive criteria (breakpoints) for Enterobacteriaceae and Pseudomonas aeruginosa: I. Cephalosporins and aztreonam","volume":"56","author":"Dudley","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2016.11.018_bib0030","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s10156-011-0285-3","article-title":"Investigation of the clinical breakpoints of piperacillin\u2013tazobactam against infections caused by Pseudomonas aeruginosa","volume":"18","author":"Yamagishi","year":"2012","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.ijantimicag.2016.11.018_bib0035","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1093\/jac\/dkf130","article-title":"Pharmacodynamics of cefepime in patients with Gram-negative infections","volume":"50","author":"Tam","year":"2002","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2016.11.018_bib0040","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/nrmicro862","article-title":"Antimicrobial pharmacodynamics: critical interactions of \u2018bug and drug","volume":"2","author":"Drusano","year":"2004","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.ijantimicag.2016.11.018_bib0045","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1592\/phco.26.9.1320","article-title":"Application of antimicrobial pharmacodynamic concepts into clinical practice: focus on \u03b2-lactam antibiotics: insights from the Society of Infectious Diseases Pharmacists","volume":"26","author":"Lodise","year":"2006","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ijantimicag.2016.11.018_bib0050","doi-asserted-by":"crossref","first-page":"4214","DOI":"10.1128\/AAC.00663-12","article-title":"Impact of antibiotic MIC on infection outcome in patients with susceptible Gram-negative bacteria: a systematic review and meta-analysis","volume":"56","author":"Falagas","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2016.11.018_bib0055","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1086\/528712","article-title":"Outcomes of bacteremia due to Pseudomonas aeruginosa with reduced susceptibility to piperacillin\u2013tazobactam: implications on the appropriateness of the resistance breakpoint","volume":"46","author":"Tam","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2016.11.018_bib0060","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1093\/cid\/cis545","article-title":"Does the piperacillin minimum inhibitory concentration for Pseudomonas aeruginosa influence clinical outcomes of children with pseudomonal bacteremia?","volume":"55","author":"Tamma","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2016.11.018_bib0065","series-title":"Summary minutes. Subcommittee on antimicrobial susceptibility testing; 6\u20137 January 2011","author":"Clinical and Laboratory Standards Institute","year":"2011"},{"key":"10.1016\/j.ijantimicag.2016.11.018_bib0070","series-title":"Meeting minutes. Enterobacteriaceae\/pseudomonas work group meeting; June 2011","author":"Clinical and Laboratory Standards Institute","year":"2011"},{"key":"10.1016\/j.ijantimicag.2016.11.018_bib0075","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.diagmicrobio.2015.03.020","article-title":"Increased antimicrobial susceptibility rates for Pseudomonas aeruginosa bloodstream isolates across the Veterans Affairs Healthcare System","volume":"83","author":"Gentry","year":"2015","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2016.11.018_bib0080","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/01.md.0000091184.93122.09","article-title":"Staphylococcus aureus bacteremia: recurrence and the impact of antibiotic treatment in a prospective multicenter study","volume":"82","author":"Chang","year":"2003","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.ijantimicag.2016.11.018_bib0085","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1097\/SHK.0b013e318182f98f","article-title":"Scoring systems for prediction of mortality in patients with intensive care unit-acquired sepsis: a comparison of the Pitt bacteremia score and the Acute Physiology and Chronic Health Evaluation II scoring systems","volume":"31","author":"Rhee","year":"2009","journal-title":"Shock"},{"key":"10.1016\/j.ijantimicag.2016.11.018_bib0090","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron"},{"key":"10.1016\/j.ijantimicag.2016.11.018_bib0095","series-title":"Zosyn (piperacillin and tazobactam injection) IV package insert","author":"Wyeth Pharmaceuticals Inc","year":"2014"},{"key":"10.1016\/j.ijantimicag.2016.11.018_bib0100","doi-asserted-by":"crossref","first-page":"4885","DOI":"10.1128\/AAC.06365-11","article-title":"Evaluation of clinical outcomes in patients with bloodstream infections due to Gram-negative bacteria according to carbapenem MIC stratification","volume":"56","author":"Esterly","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2016.11.018_bib0105","doi-asserted-by":"crossref","first-page":"4390","DOI":"10.1128\/AAC.01487-06","article-title":"Failure of current cefepime breakpoints to predict clinical outcomes of bacteremia caused by Gram-negative organisms","volume":"12","author":"Bhat","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2016.11.018_bib0110","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1177\/1077558710361486","article-title":"Applying propensity score methods in medical research: pitfalls and prospects","volume":"67","author":"Luo","year":"2010","journal-title":"Med Care Res Rev"},{"key":"10.1016\/j.ijantimicag.2016.11.018_bib0115","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1093\/eurheartj\/ehr031","article-title":"An overview of the objectives of and the approaches to propensity score analyses","volume":"32","author":"Heinze","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ijantimicag.2016.11.018_bib0120","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1177\/0272989X09341755","article-title":"The relative ability of different propensity score methods to balance measured covariates between treated and untreated subjects in observational studies","volume":"29","author":"Austin","year":"2009","journal-title":"Med Decis Making"},{"key":"10.1016\/j.ijantimicag.2016.11.018_bib0125","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.clinthera.2010.04.003","article-title":"Pharmacodynamic modeling of intravenous antibiotics against Gram-negative bacteria collected in the United States","volume":"32","author":"Koomanachai","year":"2010","journal-title":"Clin Ther"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857917300110?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857917300110?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,5]],"date-time":"2018-09-05T02:22:02Z","timestamp":1536114122000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857917300110"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["S0924857917300110"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2016.11.018","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2017,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A propensity score-matched analysis of the impact of minimum inhibitory concentration on mortality in patients with Pseudomonas aeruginosa bacteraemia treated with piperacillin\/tazobactam","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2016.11.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}